AngioDynamics Inc
NASDAQ:ANGO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
AngioDynamics Inc
NASDAQ:ANGO
|
US |
|
F
|
Feedback Technology Corp
TPEX:8091
|
TW |
|
U
|
Universal Display Corp
F:UVD
|
US |
|
OLIDATA SpA
F:OL40
|
IT |
|
James Cropper PLC
LSE:CRPR
|
UK |
AngioDynamics Inc
AngioDynamics makes medical devices that doctors use in minimally invasive procedures, especially in vascular access, vascular disease, and cancer treatment. Its products include catheters, ports, ablation tools, thrombectomy devices, and other instruments that help clinicians place access lines, remove blockages, and treat tumors or abnormal tissue. The company sells mainly to hospitals, outpatient centers, and specialist physicians. It makes money by selling these devices directly or through distribution channels, with some products used once and replaced regularly, which gives the business repeat sales tied to procedure volume. What sets AngioDynamics apart is its focus on the treatment tools used inside the body rather than broad hospital supplies. It sits in a niche part of the medical device market where its value comes from helping clinicians perform targeted procedures more safely and efficiently.
AngioDynamics makes medical devices that doctors use in minimally invasive procedures, especially in vascular access, vascular disease, and cancer treatment. Its products include catheters, ports, ablation tools, thrombectomy devices, and other instruments that help clinicians place access lines, remove blockages, and treat tumors or abnormal tissue.
The company sells mainly to hospitals, outpatient centers, and specialist physicians. It makes money by selling these devices directly or through distribution channels, with some products used once and replaced regularly, which gives the business repeat sales tied to procedure volume.
What sets AngioDynamics apart is its focus on the treatment tools used inside the body rather than broad hospital supplies. It sits in a niche part of the medical device market where its value comes from helping clinicians perform targeted procedures more safely and efficiently.
Revenue: AngioDynamics reported fourth-quarter revenue of $86.6 million, up 8%, and full-year revenue of $320.2 million, up 9.4%, with growth led by Med Tech.
Med Tech: Med Tech revenue rose 16.7% in the quarter and 18.4% for the year, as the company said its higher-growth platforms kept taking share in large markets.
NanoKnife: NanoKnife was a standout, with quarterly revenue up 64.5% and record procedures, helped by stronger prostate adoption and improving reimbursement coverage.
Mechanical Thrombectomy: This business was mixed in the quarter, with AlphaVac still growing strongly but AngioVac down, and management said it made commercial changes to improve execution.
Margins & Cash: Gross margin improved to 54% in the quarter and 54.6% for the year, while the company still generated $3.1 million of operating cash for the year and ended with a debt-free balance sheet.
FY27 Outlook: Management guided to 2027 revenue of $336 million to $341 million, gross margin of 54% to 55%, adjusted EBITDA of $13 million to $16 million, and adjusted loss per share of $0.29 to $0.24.
